Therapy-related classical Hodgkin lymphoma after a primary haematological malignancy: a report on 13 cases.
The risk of developing Hodgkin lymphoma (HL) is increased in immunodeficiencies or during the treatment of some autoimmune diseases. The development of new therapeutic agents has highlighted the risk of unusual lymphoid proliferations, particularly classical HL (cHL). We report the clinicopathological findings of 13 cHL arising in patients treated for a primary haematological malignancy. Eight patients had received an immunomodulator, protein tyrosine-kinase inhibitor or monoclonal antibody, which may have contributed to the cHL development. Most patients had disseminated disease with poor prognostic factors at cHL diagnosis. Despite the initial presentation, good outcomes were achieved with standard cHL chemotherapy.
Department of Haemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris 7-Diderot, Paris, France.
Morgane
M
Cheminant
Lionel
L
Galicier
Josette
J
Brière
David
D
Boutboul
Jean-Michel
JM
Micléa
Marie-Dominique
MD
Venon
Marie
M
Robin
Catherine
C
Thieblemont
Pauline
P
Brice
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000139:chemically induced*; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D016896:Treatment Outcome